Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sorafenib - Bayer

Next Previous
Drug Profile

Sorafenib - Bayer

Alternative Names: BAY 43-9006 Tosylate; BAY 54-9085; BAY-43-9006; BAY-439006-Tosylate-Salt; Nexavar; Sorafenib tosilate; Sorafenib tosylate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Onyx Pharmaceuticals; University of Kentucky
  • Developer ACORN Research; Asan Medical Center; Bayer; Beth Israel Deaconess Medical Center; Charite of Berlin; Genentech; Indiana University; Indiana University School of Medicine; Karolinska University Hospital; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Center (Korea); National Cancer Institute (USA); Onyx Pharmaceuticals; Oregon Health & Science University; Takeda; Thomas Jefferson University; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Yale University
  • Class Amides; Antineoplastics; Benzenesulfonates; Chlorobenzenes; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fms-like tyrosine kinase 3 inhibitors; Mitogen-activated protein kinase inhibitors; Mitogen-activated protein kinase kinase inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Raf kinase inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer; Renal cell carcinoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Gastric cancer; Glioma; Head and neck cancer; Myelodysplastic syndromes; Neurofibromatosis 1; Oesophageal cancer; Ovarian cancer; Portal hypertension; Soft tissue sarcoma
  • Suspended Malignant melanoma; Prostate cancer
  • No development reported Acute promyelocytic leukaemia; Cancer; Colorectal cancer; Glioblastoma; Gliosarcoma; Mesothelioma; Neuroendocrine tumours; Pancreatic cancer; Solid tumours; Urogenital cancer
  • Discontinued Breast cancer; Germ cell and embryonal neoplasms; Germ cell cancer; HER2 negative breast cancer; Non-small cell lung cancer; Small cell lung cancer; Testicular cancer

Most Recent Events

  • 26 Sep 2022 No development reported - Phase-II for Renal cell carcinoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Australia, New Zealand (PO)
  • 04 Jun 2021 Efficacy and adverse events data from a phase II trial in thyroid cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 28 Jul 2020 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Germany (PO, Suspension)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top